Loading company…
Waltham-based Regenacy Pharmaceuticals, founded in 2016, develops therapies for rare and chronic diseases with unmet medical needs.
Founded in 2016 and headquartered in Waltham, US, Regenacy Pharmaceuticals is a biotechnology company developing treatments for rare and chronic diseases. Revenue is mainly tied to R&D funding, collaborations and licensing agreements for its drug candidates. CEO Simon Jones has led the company since its founding. In January 2022 it raised USD 7.81 mn in Series B funding led by Cobro Ventures, alongside 3E Bioventures Capital, Taiwania Capital and Yonjin Venture.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in